Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GFER | P55789 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.41 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.41 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 4/20 | 0.37 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29858178 | 1.00 | GFER (0.45) | GFERKDM4EMAPTGRIA1GRIA2 | |
| SCHEMBL31561888 | 0.89 | CRBN (0.46) | GFERKDM4EMAPTCRBNALDH1A1 | |
| SCHEMBL5229316 | 0.89 | CRBN (0.46) | GFERKDM4EMAPTCRBNALDH1A1 | |
| SCHEMBL22829975 | 0.85 | HSD17B10 (0.47) | KDM4EMAPTGRIA1GRIA2GRIA3 | |
| SCHEMBL30832879 | 0.81 | ALOX5 (0.43) | KDM4EALDH1A1HSD17B10ALOX5DRD2 | |
| SCHEMBL14774736 | 0.81 | ALOX5 (0.43) | KDM4EALDH1A1HSD17B10ALOX5DRD2 | |
| Hydrochloric Acid SCHEMBL16195394 | 0.80 | ALOX5 (0.42) | KDM4EALDH1A1HSD17B10ALOX5DRD2 | |
| Hydrochloric Acid SCHEMBL20571437 | 0.80 | P2RX7 (0.39) | KDM4EMAPTGRIA1GRIA2GRIA3 | |
| SCHEMBL15962083 | 0.78 | KDM4E (0.47) | GFERKDM4EMAPTGRIA1GRIA2 | |
| SCHEMBL3500161 | 0.77 | TSHR (0.50) | KDM4EMAPTALDH1A1ALOX15HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104220422-B | EP1 receptors ligands | 埃斯特韦实验室有限公司 | 2017-11-07 | — | — | CN | disclosed |
| US-9518015-B2 | EP1 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| US-20140323475-A1 | EP1 RECEPTOR LIGANDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2014-10-30 | — | — | US | disclosed |
| EP-2766344-A1 | EP1 RECEPTOR LIGANDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013037960-A1 | EP1 RECEPTOR LIGANDS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-03-21 | — | — | WO | disclosed |
| EP-1340744-B1 | Hiv protease inhibitors | AGOURON PHARMA (US) | 2007-05-23 | — | — | EP | disclosed |
| US-7179918-B2 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | AGOURON PHARMACEUTICALS, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | CANAN KOCH STACIE S | 2007-01-25 | — | — | US | disclosed |
| US-7094909-B2 | Reacting an amide compound containing hydroxy and a carboxyl group and having benzene ring, with a halogenated alkyl aminocarbonyl-pyrrolidine with 2-fluoro groups substituted at the ring carbon, by amindation of amine and carboxyl group | AGOURON PHARMACEUTICALS, INC. (US) | 2006-08-22 | — | — | US | disclosed |
| CN-1195737-C | HIV proteinase inhibitor | AGOURON PHARMA (US) | 2005-04-06 | — | — | CN | disclosed |
| EP-0741719-A4 | INTERMEDIATE AND PROCESS FOR MAKING | LILLY CO ELI (US) | 1997-04-02 | — | — | EP | disclosed |
| WO-1997011069-A1 | HETEROCYCLIC COMPOUNDS AS BRADYKININ ANTAGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-03-27 | — | — | WO | disclosed |
| EP-0741719-A1 | INTERMEDIATE AND PROCESS FOR MAKING | ELI LILLY AND COMPANY (US) | 1996-11-13 | — | — | EP | disclosed |
| CN-1131942-A | HIV protease inhibitors | AGOURON PHARMACEUTICALS INS (US) | 1996-09-25 | — | — | CN | disclosed |
| EP-0722439-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-07-24 | — | — | EP | disclosed |
| US-5484926-A | VIRICIDES AND ENZYME INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1996-01-16 | — | — | US | disclosed |
| US-5461154-A | HIV protease inhibitors | ELI LILLY AND COMPANY (US) | 1995-10-24 | — | — | US | disclosed |
| WO-1995021164-A1 | INTERMEDIATE AND PROCESS FOR MAKING | ELI LILLY AND COMPANY (US) | 1995-08-10 | — | — | WO | disclosed |
| WO-1995009843-A1 | HIV PROTEASE INHIBITORS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-04-13 | — | — | WO | disclosed |
| US-4117135-A | NOVEL 5,6,7,8-TETRAHYDRO-5-QUINOLINES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING, A.G. | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021354-A1 | HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis | SERPINB1, PEPD, PREP | GFER 3636/4885KDM4E 2162/4885MAPT 1282/4885 |
| US-20140323475-A1 | EP1 RECEPTOR LIGANDS | PTGER1, PTGER2, PTGIR | GFER 2208/4885KDM4E 3864/4885MAPT 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.